Core Viewpoint - The company has received formal acceptance for its clinical trial application for the new veterinary drug, Isupatide α, aimed at treating diabetes in pets, which is expected to begin Phase I clinical trials in the first quarter of 2026 [1] Group 1: Product Development - The company’s core product, Isupatide α, is intended for the treatment of diabetes in pets, indicating a strategic move into the pet pharmaceutical market [1] - The board believes that developing diabetes medication for pets has significant potential due to increasing consumer willingness to spend on extending pet lifespans [1] Group 2: Regulatory Compliance - The company has complied with all relevant standards and regulatory requirements for veterinary drug research and registration as mandated by the Ministry of Agriculture [1] - Successful completion of preclinical trials has been achieved, demonstrating positive progress in efficacy and safety for Isupatide α in managing pet diabetes [1]
银诺医药-B(02591)：依苏帕格鲁肽α的新兽药临床试验申请获受理